Literature DB >> 10463719

Are surrogate markers adequate to assess cardiovascular disease drugs?

R Temple1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10463719     DOI： 10.1001/jama.282.8.790

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  66 in total

Review 1.  Biomarkers as surrogates for cancer development.

Authors:  E Hawk; J L Viner; J A Lawrence
Journal:  Curr Oncol Rep       Date:  2000-05       Impact factor: 5.075

Review 2.  Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents.

Authors:  R S Chen; P Lapuerta
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 3.  Lessons learned from prematurely terminated clinical trials.

Authors:  D Sica
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

4.  Assessing the cost-effectiveness of pharmacogenomics.

Authors:  D L Veenstra; M K Higashi; K A Phillips
Journal:  AAPS PharmSci       Date:  2000

Review 5.  Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).

Authors:  Marissa N Lassere; Kent R Johnson; Michal Schiff; David Rees
Journal:  BMC Med Res Methodol       Date:  2012-03-12       Impact factor: 4.615

6.  Retinectomy for intractable glaucoma.

Authors:  V W Y Wong; T Y Y Lai; D S C Lam
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

7.  Medical imaging in new drug clinical development.

Authors:  Yi-Xiang Wang; Min Deng
Journal:  J Thorac Dis       Date:  2010-12       Impact factor: 2.895

Review 8.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

9.  Evaluating surrogate marker information using censored data.

Authors:  Layla Parast; Tianxi Cai; Lu Tian
Journal:  Stat Med       Date:  2017-01-15       Impact factor: 2.373

Review 10.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.